Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Ranging Study of Quadrivalent HPV Vaccine (V501-007)
NCT00365716Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2000
- Primary completion
- May 2004
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (5 arms), sponsored by Merck & Co. Primary endpoint: Number of Subjects With Injection Site Adverse Experiences. Started May 2000; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00365716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365716.